A phase I clinical trial of intrahepatic artery delivery of TG6002 in combination with oral 5-fluorocytosine in patients with liver-dominant metastatic colorectal cancer.
West EJ, Sadoun A, Bendjama K, Erbs P, Smolenschi C, Cassier PA, de Baere T, Sainte-Croix S, Brandely M, Melcher AA, Ismail F, Scott KJ, Bennett A, Banks E, Gasior E, Kent S, Kurzawa M, Hammond C, Patel JV, Collinson FJ, Twelves C, Anthoney DA, Swinson D, Samson A.
West EJ, et al. Among authors: ismail f.
Clin Cancer Res. 2025 Jan 9. doi: 10.1158/1078-0432.CCR-24-2498. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39785814